Keywords: AstraZeneca, Brilinta, FDA advisory, Acute coronary syndromes, Second-quarter 2010 financial results
US FDA advisory panel backs AstraZeneca’s Brilinta, as firm posts 22% rise in core EPS for 2nd-qtr 2010
Article | 29 July 2010
The US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee has recommended the approval of Anglo-Swedish drug major ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
